Salute e Benessere

New data with daridorexant assessing the transition from night to day in…

Daridorexant improved sleep maintenance throughout the entire night, including the last quarter, while also improving next-morning sleepiness.Daridorexant improved next-morning sleepiness compared to placebo from as early as the first day of treatment.Daridorexant improved daytime ability to function and daytime alertness each week over the 3-month treatment duration.Allschwil, Switzerland – April 29, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of “ Effect of...
Nasdaq GlobeNewswire
29/04/2025

Roche granted FDA Breakthrough Device Designation for first AI-driven companion…

The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level of diagnostic precision not possible with traditional manual scoring methods. This Breakthrough Device Designation (BDD) demonstrates Roche's continued innovation in companion diagnostics and digital pathology to enable more precise diagnosis in oncology...
Nasdaq GlobeNewswire
29/04/2025

Amorepacific Research Confirms Potential of Microalgal-Derived PDRNs in Skin…

PDRNs have been garnering attention in recent years for its efficacy in enhancing skin regeneration and wound healing. In Korea, PDRNs that have been purified can be found in various applications, including pharmaceuticals, medical devices and cosmetics. Traditionally, PDRNs are extracted from animal-derived sources like salmon or trout, but Amorepacific turned its attention to Chlorella protothecoides to develop an animal-free alternative that is sustainable and scalable. PDRNs have been...
PR Newswire
29/04/2025

UK Company, Stablepharma Ltd, enters Phase 1 Clinical Trials with world-first…

Stablepharma Ltdhas commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National Institute for Health and Care Research (NIHR) at Southampton Clinical Research Facility.Stablepharma's pioneering science has progressed into the clinical trial stage thanks to funding from shareholders and the UK Government, including Innovate UK and...
Nasdaq GlobeNewswire
29/04/2025

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: Illuccix, after radiolabelling with gallium-68, is indicated inFrancefor the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: PSMA-PET [3]imaging...
PR Newswire
29/04/2025

Novartis' VANRAFIA Approval Disrupts IgA Nephropathy Market, Paving Way for New…

The IgA nephropathy treatment approach aims to reduce proteinuria, manage blood pressure, and slow the progression of the disease. First-line IgA nephropathy treatment typically involves angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), with sodium-glucose co-transporter 2 (SGLT2) inhibitors providing added kidney protection. Emerging targeted therapies like sparsentan—a dual endothelin receptor antagonist and angiotensin receptor blocker—and…
PR Newswire
28/04/2025

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025- Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April28, 2025(GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the...
Nasdaq GlobeNewswire
28/04/2025

Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the…

The data are presented in two posters: Title: TALEN®- Mediated non-viral Transgene Insertion for the Advancement of Cellular and Gene Therapies. Cell and gene therapy approaches can use gene-editing tools and introduce transgenes to modify disease-associated genes, thus providing a potential therapeutic solution for a wide array of diseases.In this work, Cellectis combines TALEN®-mediated gene editing with non-viral delivery of transgene for advancing cellular and gene therapies, and...
Nasdaq GlobeNewswire
28/04/2025

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary…

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025-GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen will be presenting data from its late-breaking abstract on elafibranor, highlighting favorable safety profile and significant efficacy in Primary Sclerosing Cholangitis (PSC), at the European Association for the...
Nasdaq GlobeNewswire
28/04/2025

Purina Institute Announces 2025 Webinar Series on Pet Nutrition Conversations…

Research shows that veterinarians are pet owners' most trusted source for nutrition advice.¹ In addition, 78% of surveyed pet owners rated nutrition expertise as an "important" or "extremely important" factor in their satisfaction with their veterinary clinic. Research shows that veterinarians are pet owners'most trusted sourcefor nutrition advice.¹ In addition, 78% of surveyed pet owners rated nutrition expertise as an "important" or "extremely important"…
PR Newswire
28/04/2025

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN…

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVEDFY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION;EBITDA (1)BETWEEN € 1,140 AND € 1,225 MILLION;ADJUSTED NET INCOME (2)BETWEEN € 770 AND € 820 MILLIONMilan, 28 thApril 2025– The Board of Directors of Recordati S.p.A. has reviewed and approved the plan for the 2025-2027 three-year period. Recordati will continue executing on its strategy focused on driving organic growth of its current product...
Nasdaq GlobeNewswire
28/04/2025

IBA – ACQUISITION OF OWN SHARES

Immediate Release – April 28 th, 2025 Louvain-la-Neuve, Belgium, April 28 th, 2025 -In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24 th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the...
Nasdaq GlobeNewswire
28/04/2025

Virbac : Public release of Virbac Annual Report at 31 December 2024

The Group released and filed its 2024 Annual Report with the French “Autorité des marchés financiers”, at the ESEF Format.Additionally, the report is attached at the PDF format.The document is also available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports” at the ESEF format and PDF format. Attachments Public release of Virbac Annual Report at 31 December 2024Annual_report_Virbac_2024
Nasdaq GlobeNewswire
28/04/2025

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate…

The expanded rollout will continue to contribute to AstraZeneca's global real-world evidence initiatives and help further validate the clinical impact of decentralized liquid biopsy testing across diverse healthcare systems. By increasing the availability of MSK-ACCESS® powered with SOPHiA DDM™, SOPHiA GENETICS and AstraZeneca aim to understand further how liquid biopsy testing can complement solid tissue testing and, in some cases, provide greater benefit for labs and patients. The expanded...
PR Newswire
28/04/2025

IBA – TRANSPARENCY NOTIFICATION

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, April 28 th, 2024 06:00 PM Summary of the notificationIBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification...
Nasdaq GlobeNewswire
28/04/2025

Press release: Sequana Medical Announces New Share Capital Amount and New Number…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 28 April 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yield LLC SCS (" GEM "), the Company's share capital has increased on 28 April 2025 from EUR…
Nasdaq GlobeNewswire
28/04/2025

Eurobio Scientific: 2024 annual results

2024 ANNUAL RESULTS Growth of core business and strategic execution Revenue up 19% to €154 millionOrganic growth at +9%Proprietary products account for a stable 31% of group revenueInternational accounts for 41% of group revenueStable 2024 operational results, reflecting pressure on margins and underperformance of some European subsidiariesFree cash flow of €6 millionNet debt of €3.9 million, including EB Development current account Paris, April 28,...
Nasdaq GlobeNewswire
28/04/2025

Real-world study across 1,000+ NHS GP practices shows AI-led triage detected 20%…

The study, which evaluated over 235,000 patient risk assessments conducted across 1,084 GP practices between January 2020 and September 2024, found that: The study, which evaluated over 235,000 patient risk assessments conducted across 1,084 GP practices betweenJanuary 2020andSeptember 2024, found that: C the Signs uses AI to analyse clinical data in under 60 seconds — identifying patients at risk, recommending the most appropriate pathway, and streamlining cancer diagnosis. By...
PR Newswire
28/04/2025

Live Cell Imaging Market worth US$4.75 billion in 2030 with 8.68% CAGR |…

Browse in-depth TOC on "Live Cell Imaging Market" Browse in-depth TOC on "Live Cell Imaging Market" 293 - Tables 50 - Figures 293 - Pages By Based on offerings,the live cell imaging market is divided into products, software, and services. The product segment is further subdivided into instruments and consumables. In 2024, the product segment held the largest share of the live cell imaging market by offering. The large share of the product segment can be attributed to...
PR Newswire
28/04/2025

AI In Healthcare Market Size to Reach $187.7 Billion by 2030 at CAGR 38.5% -…

Request a free sample copy or view report summary - AI In Healthcare Market Request a free sample copy or view report summary -AI In Healthcare Market AI algorithms are developed by leveraging patient health data to enhance disease identification and early detection, which allows for the prompt commencement of treatment plans. Crucial factors fueling market expansion include supportive government programs, financial backing, an increasing influx of investments from private investors...
PR Newswire
28/04/2025

Olon Group Strengthens Its Leadership in Bioproduction with Two Strategic…

An Integrated Vision for ADCs, HPAPIs, and Microbial Bioproduction With this new leadership structure, Olon Group is accelerating the development of its fully integrated ADC offering, covering the entire value chain from Cell Line Development (CLD) to drug product manufacturing, including payload and linker production. This comprehensive approach enables biotech companies and pharmaceutical firms to access a seamless CDMO solution for next-generation targeted therapies. Olon Group is also...
Nasdaq GlobeNewswire
28/04/2025

LILYSILK Celebrates Mother's Day with Heartfelt Film and Exclusive Gift…

As part of the campaign, LILYSILK has launched a limited-edition collection featuring delicate "Mom" embroidery across four best-selling items: As part of the campaign, LILYSILK has launched a limited-edition collection featuring delicate "Mom" embroidery across four best-selling items: These thoughtfully selected pieces are available at a special 40-60% discount for a limited time viawww.lilysilk.com/us/page/mothers-day-2025. LILYSILK's Mother's Day offerings arrive in…
PR Newswire
28/04/2025

KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY…

The study included data from 33 subjects who participated in the U.S. Phase 2 trial and 110 subjects from the Phase 3 trial who completed two years of follow-up. The ongoing Phase 3 trial data were analyzed in a blinded manner, including both TG-C and placebo arms, allowing for an objective evaluation of the long-term safety and treatment effects. The study included data from 33 subjects who participated in the U.S. Phase 2 trial and 110 subjects from the Phase 3 trial who completed two years...
PR Newswire
28/04/2025

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 28, 2025 – Genmab A/S (Nasdaq: GMAB).On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.The following transactions were executed under the program from April 21 to April 25, 2025: Trading Platform...
Nasdaq GlobeNewswire
28/04/2025
Altri  Comunicati